Investors & Media

Press Releases

Date Title View
Toggle Summary Sage Therapeutics to Present at American Epilepsy Society 70th Annual Meeting
CAMBRIDGE, Mass. --(BUSINESS WIRE)-- Sage Therapeutics  ( NASDAQ : SAGE), a clinical-stage biopharmaceutical company developing novel medicines to treat life-altering central nervous system (CNS) disorders, today announced upcoming presentations at the American Epilepsy Society (AES) 70 th Annual
View HTML
Toggle Summary SAGE-547 Granted PRIME Designation by EMA for the Treatment of Postpartum Depression
New EMA regulatory designation offers potential for increased dialogue and accelerated assessment of future EU regulatory application Decision based on positive placebo-controlled Phase 2 results SAGE PPD studies in moderate and severe PPD ongoing with top-line results expected in 2017 Company now
View HTML
Toggle Summary Sage Therapeutics to Present at Society for Neuroscience 2016 Annual Meeting
CAMBRIDGE, Mass. --(BUSINESS WIRE)-- Sage Therapeutics  ( NASDAQ : SAGE), a clinical-stage biopharmaceutical company developing novel medicines to treat life-altering central nervous system (CNS) disorders, today announced upcoming presentations at the Society for Neuroscience (SFN) 2016 Annual
View HTML
Toggle Summary Sage Therapeutics to Present at the Stifel 2016 Healthcare Conference
CAMBRIDGE, Mass. --(BUSINESS WIRE)-- Sage Therapeutics  ( NASDAQ : SAGE), a clinical-stage biopharmaceutical company developing novel medicines to treat life-altering central nervous system (CNS) disorders, today announced that Jeff Jonas, M.D., Chief Executive Officer of Sage, will present at the
View HTML
Toggle Summary Sage Therapeutics Announces Third Quarter 2016 Financial Results and Provides SRSE European Update
  Positive Scientific Advice From European Medicines Agency on Development of SAGE-547 in SRSE Provides Regulatory Path in E.U. Ongoing Phase 3 STATUS Trial Expected to be Sufficient to Support a European Marketing Authorization Application for SAGE-547 in SRSE Eight Clinical Trials Across
View HTML
Toggle Summary Sage Therapeutics to Report Third Quarter 2016 Financial Results on Thursday, November 3, 2016
CAMBRIDGE, Mass. --(BUSINESS WIRE)-- Sage Therapeutics  ( NASDAQ : SAGE), a clinical-stage biopharmaceutical company developing novel medicines to treat life-altering central nervous system (CNS) disorders, today announced that the company will host a conference call and live webcast on Thursday,
View HTML
Toggle Summary Sage Therapeutics and Collaborators Publish New Pre-clinical Data in Neuropharmacology Demonstrating a Novel Metabotropic Mechanism of Sage Compounds Resulting in Enhanced Effects
In vitro data show short exposure to certain neuroactive steroids, including allopregnanolone and novel Sage tool compound SGE-516, can have sustained effects through enhancement of extrasynaptic GABA A receptor surface expression SAGE-547, Sage's proprietary intravenous formulation of
View HTML
Toggle Summary Sage Reports Additional Positive Data on Secondary Endpoints from Phase 2 Clinical Trial of SAGE-547 in Severe Postpartum Depression at the Marcé Society for Perinatal Mental Health Biennial Scientific Meeting
Secondary endpoints showed significant difference in improvement from baseline for SAGE-547 compared to placebo over three weeks following end of treatment Data are consistent with previously reported top-line results, including primary endpoint achieved with statistical significance at 60 hours
View HTML
Toggle Summary Sage Therapeutics to Present at the Leerink Partners Rare Disease Roundtable
CAMBRIDGE, Mass. --(BUSINESS WIRE)-- Sage Therapeutics  ( NASDAQ : SAGE), a clinical-stage biopharmaceutical company developing novel medicines to treat life-altering central nervous system (CNS) disorders, today announced that Jeff Jonas, M.D., Chief Executive Officer of Sage, will present at the
View HTML
Toggle Summary Sage Therapeutics to Present at the Neurocritical Care Society 14th Annual Meeting
CAMBRIDGE, Mass. --(BUSINESS WIRE)-- Sage Therapeutics (NASDAQ:SAGE), a clinical-stage biopharmaceutical company developing novel medicines to treat life-altering central nervous system (CNS) disorders, today announced upcoming poster presentations at the Neurocritical Care Society 14th Annual
View HTML